Solventum Corp

NYSE: SOLV·Maplewood, Minnesota·

Price
$88.65
Base IV
$57.94

Valuation snapshot

Above base case

At $88.65, the price sits between our base case ($57.94) and bull case ($99.26).

Values per share, from an .

No growth
…
Loading earnings power
Base case
$57.94
65% of the price · range $24.28–$99.26
Price vs base case
53% above
$88.65 against $57.94
Base casevalued by DCF
Price vs base
Priceclose 11‑16

Whisker on the base case runs bear $24.28 to bull $99.26. Values per share.

Price against each value

Bear case
$24.28
Price 265% above
No growth
…
—
Base case
$57.94
Price 53% above
Researched byClaude Opus 5.5
Valuation Nov 15, 2026 · Price as of Nov 16, 2026How we got here

What does Solventum do?

Solventum provides medical supplies, dental products, and healthcare software to hospitals and clinics to manage patient care, improve clinical workflows, and reduce administrative burdens.

It brought in $8.2B of sales in the 12 months to Sep 2026.

Led by Bryan Hanson, Chief Executive Officer since 2023. Solventum Leadership - Bryan Hanson

Industry
Healthcare
Based in
Maplewood, Minnesota
Trades on
NYSE as SOLV

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 2¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 45¢ of every dollar.

  • Making what it sells45¢
  • Research and development9¢
  • Sales, marketing and admin41¢
  • Interest and other costs3¢
  • Left as profit2¢
Totals of the four quarters to Sep 2026, from the company's own filings. The split by product is from the latest fiscal year.

Who pays Solventum, and for what?

Solventum is a healthcare company that was split off from 3M in 2024. It makes and sells medical supplies such as wound-care products, infection-prevention and surgical supplies, and dental and orthodontic products. It also sells software that helps hospitals with medical records, billing and coding. Most of its money comes from selling these products and software licences.

Hospitals, clinics, dentists, orthodontists and health systems in more than 90 countries pay Solventum, and they are often paid in turn by government programmes such as Medicare and Medicaid or by private insurers.

  • MedSurg

    58%

    Wound-care therapies and dressings, I.V. site care, sterilisation checks, patient warming, surgical supplies, medical tapes, stethoscopes and parts made for other device makers.

  • Health Information Systems

    16%

    Software that helps hospitals with medical records, coding and billing, plus speech recognition and data tools, to reduce paperwork and make sure hospitals are paid correctly.

  • Dental Solutions

    16%

    Dental and orthodontic products such as brackets, clear aligners, fillings, cements and bonding agents, covering prevention through to restoration.

  • Purification and Filtration (sold)

    6%

    Filtration products for industry and life sciences. This business was sold to Thermo Fisher in September 2025 for about $4 billion, so it only counts for part of 2025.

  • All Other

    4%

    Mainly the drinking-water filtration business Solventum kept, plus agreements to supply products to 3M and some former 3M customers.

Share of the latest fiscal year's sales, as the company reports it.

Where its work physically happens, beyond headquarters:

  • Brookings Manufacturing Plant — Brookings, United States. Solventum's largest plant, making MedSurg essentials such as IV site securements and surgical drapes; management says it generates over 10% of global revenue, and a $220M expansion that added manufacturing and distribution capacity was finished in April 2026.
  • Eagan Innovation Hub — Eagan, United States. A new 250,000 sq ft flagship R&D center (about $200M) with a pilot factory and a dedicated quality lab, built to speed products from the lab to production; it is also the future principal office under a finance lease running to 2046 (current HQ: 3M Center, Maplewood).
  • Seefeld Plant — Seefeld, Germany. A major German manufacturing site and one of the 14 plants outside the U.S. disclosed in the 10-K; it is a focus of Solventum's sustainability spending, including an industrial heat pump expected to cut the plant's greenhouse gas emissions by about 17%.
  • KCI Manufacturing Athlone — Athlone, Ireland. Home of KCI Manufacturing Unlimited Company, the Irish manufacturing entity of the former KCI/Acelity wound-care business inside the MedSurg segment, and part of the Ireland manufacturing footprint disclosed in the 10-K.
See them on the globe

Solventum 2025 Annual Report (Form 10-K)

How is the business doing?

Sales have barely moved over 2 years, from $8.2B in 2023 to $8.3B in 2025.

Running the business leaves about 6¢ of each sales dollar as operating profit, down from 21¢ in 2023.

After paying for its upkeep and new investment, it had $0 of cash to spare in the 12 months to Sep 2026.

Sales$8.3B
20232025
Operating margin26%
20232025
Free cash flow-$10M
20232025
Each bar is one fiscal year (2023–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

Solventum says it exists to make healthcare better, smarter and safer so that patients' lives improve.

“Our employees are united in our mission to provide better, smarter, safer healthcare to improve lives.”

Solventum 2025 Annual Report (Form 10-K)

Who is responsible for the plan?

Roles checked November 6, 2026.

What management says it is working on now:

  • Finishing the split from 3M

    Solventum still relies on 3M for some manufacturing, shipping and back-office services. In mid-2026 it said it had moved about 950 of roughly 1,200 computer systems off 3M's and had ended nearly 70% of its temporary service agreements with 3M. It aims to have ended 90% of those agreements by the end of 2026.

    Solventum Q2 2026 Earnings Call Transcript
  • Separating the health software business

    In August 2026, Solventum announced that it plans to separate its Health Information Systems software business. This would leave the company focused on its medical-surgical and dental products.

    Solventum Announces Intent to Separate its Health Information Systems Business
  • Paying down debt

    After the 3M split, Solventum had about $5 billion of debt at the end of 2025. It used money from selling its filtration business to repay some of that debt, and management lists paying down debt as its first use of cash.

    Solventum 2025 Annual Report (Form 10-K)
  • Reshaping its range of businesses

    In 2025, Solventum sold its Purification and Filtration business and bought Acera Surgical, a maker of synthetic tissue products. It says it will keep buying and selling businesses where that improves the company.

    Solventum 2025 Annual Report (Form 10-K)
  • Protecting profits from rising costs

    In 2025, profits were squeezed by new tariffs of about $55 million, higher shipping costs and higher prices on products bought from 3M. Management is using cost-saving programmes and other suppliers to make up for this.

    Solventum 2025 Annual Report (Form 10-K)
Organic sales growth, full year 2026
2.5% to 3.0% (3.5% to 4.0% excluding products it is dropping)
Solventum Q2 2026 Shareholder Letter
Adjusted earnings per share, full year 2026
$7.10 to $7.20
Solventum Q2 2026 Shareholder Letter
Free cash flow, full year 2026
$200 million to $300 million
Solventum Q2 2026 Shareholder Letter
Organic sales growth, by 2028 (2025 plan; to be updated in early 2027 after the software separation)
4% to 5% per year
Solventum 2025 Investor Day Presentation
Operating margin, by 2028 (2025 plan)
23% to 25%
Solventum 2025 Investor Day Presentation
Earnings per share growth, through 2028 (2025 plan)
About 10% per year
Solventum 2025 Investor Day Presentation
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is slowing. In Q3 2026 it sold 7% less than a year earlier. The year before, quarters averaged -1%.

Its operating margin is narrower than a year ago: 3¢ per sales dollar, against 81¢.

Since Oct 2026 the share price has risen 6%, from $83.56 to $88.65.

Bull $99.26Base $57.94Bear $24.28Oct 30Nov 16 · $88.65
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start October 30, 2026.

Recently

Coming up

  • Expected within 12 to 18 months of August 2026, subject to approvals

    Health software business separation

    Solventum plans to separate its Health Information Systems business. The options range from a stand-alone listed company to a deal with another firm, and the structure has not been decided.

    Solventum Announces Intent to Separate its Health Information Systems Business
  • By end of 2026

    Ending temporary service agreements with 3M

    Management aims to have ended 90% of its temporary service agreements with 3M and to have finished most of its move to its own computer systems.

    Solventum Q2 2026 Earnings Call Transcript
  • First quarter of 2027

    Investor Day with new long-range plan

    Solventum plans to set out a new long-term plan for the company without the software business, including an update on its pipeline of new products.

    Solventum Q2 2026 Earnings Call Transcript
  • By around April 2029

    3M selling its remaining shares

    3M still owns about 14.8% of Solventum and is expected to sell that stake within five years of the April 2024 split. The timing of those sales could affect the share price.

    Solventum 2025 Annual Report (Form 10-K)

Our own estimate moved too: the base case went from $26.15 to $57.94 a share between our last two valuations. The biggest reason: Adjusted operating margin, quarterly moved from 28.4% to 19.9%, as reported in Q3 2026 call highlights.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Large debt load

    Solventum took on debt when it split from 3M and still owed about $5 billion at the end of 2025. Interest payments use up cash that could otherwise go into the business, and the debt leaves the company less room to act if conditions get worse.

    From the company's own filingsWould hit how much it has to reinvestSolventum 2025 Annual Report (Form 10-K)

  2. Untangling from 3M

    Solventum still depends on 3M for some manufacturing, shipping and systems. Delays, extra costs or disruption while it moves to its own systems could hurt sales and profits, and the supply deals with 3M have already raised its costs.

    From the company's own filingsWould hit how much of each sale it keepsSolventum 2025 Annual Report (Form 10-K)

  3. Tariffs and rising costs

    New tariffs and higher shipping costs lowered profit margins in MedSurg and Dental in 2025. Future trade policy, including what follows a February 2026 Supreme Court ruling on tariffs, is uncertain.

    From the company's own filingsWould hit how much of each sale it keepsSolventum 2025 Annual Report (Form 10-K)

  4. Pressure on healthcare prices

    Governments and insurers in the U.S., China and elsewhere are trying to hold down healthcare spending. This could limit the prices Solventum can charge, or make hospitals less likely to choose its products.

    From the company's own filingsWould hit how fast sales growSolventum 2025 Annual Report (Form 10-K)

  5. Strong competitors

    Solventum competes with large companies such as Smith & Nephew, Becton Dickinson, Straumann, Align, Epic and Microsoft. In 2025, sales of its doctor-productivity software and traditional orthodontic products fell.

    From the company's own filingsWould hit how fast sales growSolventum 2025 Annual Report (Form 10-K)

  6. Lawsuits and tax obligations to 3M

    Solventum may have to pay 3M for some uninsured claims over its Bair Hugger patient-warming product, or for taxes if the split from 3M loses its tax-free status. It also relies on 3M to cover some past chemical-related (PFAS) claims.

    From the company's own filingsSolventum 2025 Annual Report (Form 10-K)

  7. Q3 2026 organic sales declined 2.8%, and Dental fell 7.4%.

    From our researchWould hit how fast sales growSolventum Q3 2026 earnings release

  8. Q3 2026 free cash flow of $97M was helped by a one-off IEEPA tariff refund.

    From our researchWould hit how much it has to reinvestQ3 2026 call highlights

Is it a good business?

From 2023 to 2025 it earned between 8% and 19% on the capital invested in it, a median of 12%. Its cost of capital in the latest valuation is 7.7%; returns were above it in every one of the 3 years.

From 2023 to 2025 it earned between 12% and 31% on its shareholders' equity, a median of 16%.

Over 3 years its operating margin ranged from 13¢ to 26¢ per sales dollar, a median of 21¢. Gross margin ran from 53¢ to 57¢.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on invested capital19%
20232025

Cost of capital 7.7%

Return on equity31%
20232025
Return on invested capital is operating profit after tax (at the median effective rate, 19%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

It bought back shares: the count fell 2.6% in a year, so each remaining share owns a slightly bigger slice.

It owes $4.8B more than it holds in cash, about 10.6 years of operating profit.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $88.65. Our put its value between $24.28 and $99.26, with $57.94 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $24.28

Sales have been roughly flat for three years and fell in the latest quarter; this scenario assumes Solventum stays a slow grower whose profits stay squeezed for years by the costs of splitting off parts of the business.

Base case, $57.94

After three years of roughly flat sales, this scenario assumes Solventum returns to steady low-single-digit growth as its system-switch disruption fades and its profits recover once one-time separation costs roll off.

Bull case, $99.26

Although sales have been nearly flat since 2023, this scenario assumes Solventum finishes its split from 3M, grows faster with its wound-care and health-software products, and becomes noticeably more profitable.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects more than we do.Price above value: 53%

For Solventum to be worth today's $88.65, sales would need to grow about 10.4% a year. We assume 3.3%.

−2.5%0%+2.5%+5%+7.5%+10%+12.5%We assume 3.3%Price needs 10.4%

Or, if sales grow 3.3% as we assume, the price works with a profit margin of 21.7% (we assume 16.0%).

Keep in mind: this is one way to read the price. Investors might be expecting other things, like higher profits or lower risk.

Do you think sales can grow 10.4% a year?

Try your own numbers

We're not very sure of this range: it scores 46 out of 100 on our checks. The weakest point is terminal-value dependency.

Test the assumptions

Our base value of $57.94 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average3.3%
  • Operating margin16.0%
  • Long-term growth rate2.5%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$57.94 -34.6%

Build